Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer - Oliver Sartor

February 5, 2019

Neal Shore and Oliver Sartor cover the topic of racial disparities in prostate cancer and the use of immunotherapy particularly sipuleucel-T in the African American community.  Oliver does a deep dive into the double-blind, placebo-controlled, multicenter trial, Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) study, involving 512 men with metastatic castration-resistant prostate cancer, with overall survival as the primary end point. 


A. Oliver Sartor, MD, is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center and the Laborde Professor for Cancer Research, with appointments in both the Medicine and Urology Departments.

Neal Shore, MD, FACS Board Certified Urologist, Medical Director of the Carolina Urologic Research Center, Atlantic Urology Clinics